C-AMOQCuraSen
adrenergic receptor agonists, noradrenergic restoration, small molecules
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-AMOQ
C-AMOQC-AMOQadrenergic receptor agonists, noradrenergic restoration, small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
CuraSen adrenergic receptor agonists, noradrenergic restoration, small molecules
CuraSen is a privately funded biopharmaceutical company developing novel treatments for psychiatric and neurodegenerative diseases. Its approach focuses on restoring noradrenergic stimulus by directly activating specific adrenergic receptor targets, especially beta-2 and alpha-1A adrenoceptors. The company is advancing programs for neurogenic orthostatic hypotension and neurodegenerative disease, including Parkinson's disease and Alzheimer's disease.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
CuraSen — Translational · Lower middle. Derived deterministically from 8 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (3 programs at…
Source: Deterministic